123 results match your criteria: "Clinic of Pediatric Hematology and Oncology[Affiliation]"

Intrachromosomal amplification of chromosome 21 (iAMP21) B-cell precursor acute lymphoblastic leukemia (BCP-ALL) in children is a high-risk subtype for which targeted drugs are lacking. In this study, we determined the frequency of secondary lesions in 28 iAMP21 BCP-ALL patient samples and investigated cellular sensitivity for candidate-targeted drugs. iAMP21 was enriched in aberrations (10.

View Article and Find Full Text PDF

Anti-CD19 chimeric antigen receptor T cells (CAR) are a well-established treatment option for children and young adults suffering from relapsed/refractory B-lineage acute lymphoblastic leukemia. Bridging therapy is used to control disease prior to start of lymphodepletion before CAR infusion and thereby improve efficacy of CAR therapy. However, the effect of different bridging strategies on outcome, side effects and response to CAR therapy is still poorly understood.

View Article and Find Full Text PDF

Clinical relevance of feto-maternal microchimerism in (hematopoietic stem cell) transplantation.

Semin Immunopathol

December 2024

Division of Pediatric Stem Cell Transplantation and Immunology, Clinic of Pediatric Hematology and Oncology, University Medical Center Hamburg-Eppendorf, 20246, Hamburg, Germany.

Toleration of a semi-allogeneic fetus in the mother's uterus as well as tolerance after allogeneic hematopoietic stem cell transplantation (HSCT) appear to share some immunologic concepts. The existence of microchimeric cells, and the original idea of a bidirectional cell trafficking between mother and child during pregnancy have been known for decades. Today, origins and mechanisms of persistence of microchimeric cells are intensively being elucidated.

View Article and Find Full Text PDF
Article Synopsis
  • Patients with JAGN1 mutations experience severe congenital neutropenia, leading to high rates of bacterial infections and poor response to G-CSF therapy.
  • Two unrelated patients, one pregnant and one an infant, received GM-CSF after G-CSF failure, but neither showed an increase in neutrophil counts and treatment was eventually stopped due to further declines and infections.
  • Despite the promising results in a mouse model, GM-CSF therapy did not benefit the patients, highlighting the need for early evaluation for hematopoietic stem cell transplantation in these cases.
View Article and Find Full Text PDF

Hemophagocytic Lymphohistiocytosis in the Context of Hematological Malignancies and Solid Tumors.

Adv Exp Med Biol

August 2024

Divisions of Immunobiology and Bone Marrow Transplantation/Immune Deficiency, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH, USA.

Hemophagocytic lymphohistiocytosis (HLH) has been described for decades in association with malignancies (M-HLH). While its mechanism is unknown, M-HLH has a poor prognosis, ranging from 10% to 30% overall survival. Mature T-cell lymphomas, diffuse large B-cell lymphoma, and Hodgkin lymphoma, with or without viral co-triggers such as Epstein-Barr virus, are among the most frequent underlying entities.

View Article and Find Full Text PDF

Ataxia-telangiectasia (A-T) is an autosomal-recessive disorder caused by pathogenic variants (PVs) of the ATM gene, predisposing children to hematological malignancies. We investigated their characteristics and outcomes to generate data-based treatment recommendations. In this multinational, observational study we report 202 patients aged ≤25 years with A-T and hematological malignancies from 25 countries.

View Article and Find Full Text PDF
Article Synopsis
  • Acute lymphoblastic leukemia (γδ T-ALL) is a rare and complex condition in children, prompting a study of 200 pediatric cases to identify its clinical and genetic characteristics.
  • The research revealed that very young children (under 3 years) with γδ T-ALL face a significantly high risk and display specific genetic changes, particularly involving STAG2 inactivation and LMO2 activation.
  • Importantly, their findings suggest that targeting DNA repair pathways linked to STAG2 inactivation with specific drugs could offer new treatment options and help classify patients based on their risk levels.
View Article and Find Full Text PDF

Osteosarcoma is a type of bone cancer that primarily affects children and young adults. The overall 5-year survival rate for localized osteosarcoma is 70-75%, but it is only 20-30% for patients with relapsed or metastatic tumors. To investigate potential glycan-targeting structures for immunotherapy, we stained primary osteosarcomas with recombinant C-type lectin CD301 (MGL, CLEC10A) and observed moderate to strong staining on 26% of the tumors.

View Article and Find Full Text PDF

Diagnostic leukapheresis reveals distinct phenotypes of NSCLC circulating tumor cells.

Mol Cancer

May 2024

Department of Personalized Oncology, DKFZ-Hector Cancer Institute, University Medical Center Mannheim, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany.

Article Synopsis
  • Circulating tumor cells (CTCs) are critical for understanding tumor diversity and treatment resistance, but traditional methods often capture low numbers, especially in non-small cell lung cancer (NSCLC).
  • This study utilized diagnostic leukapheresis (DLA) on six advanced NSCLC patients to access larger blood volumes and employed a new two-step method to enrich CTCs for analysis.
  • The results unveiled 3,363 unique CTC transcriptomes, revealing significant heterogeneity and potential distinct phenotypes, which suggests CTCs can serve as valuable indicators for tumor monitoring and targeted therapies in the future.
View Article and Find Full Text PDF

Acute lymphoblastic leukemia (ALL) arises from the uncontrolled proliferation of B-cell precursors (BCP-ALL) or T cells (T-ALL). Current treatment protocols obtain high cure rates in children but are based on toxic polychemotherapy. Novel therapies are urgently needed, especially in relapsed/refractory (R/R) disease, high-risk (HR) leukemias and T-ALL, in which immunotherapy approaches remain scarce.

View Article and Find Full Text PDF

Background: Ferritin is an established biomarker in the diagnosis of secondary hemophagocytic lymphohistiocytosis (HLH), which is diagnosed by the HLH-2004 criteria. Among these criteria, detection of hemophagocytosis through invasive procedures may delay early life saving treatment. Our aim was to investigate the value of hemophagocytosis in diagnosing HLH in critically ill patients.

View Article and Find Full Text PDF

Familial hemophagocytic lymphohistiocytosis (FHL) is an inherited, often fatal immune deficiency characterized by severe systemic hyperinflammation. Although allogeneic bone marrow transplantation can be curative, more effective therapies are urgently needed. FHL is caused by inactivating mutations in proteins that regulate cellular immunity.

View Article and Find Full Text PDF

Objective: The aim was to assess postoperative outcomes in pediatric thyroid nodules with atypia of undetermined significance (AUS/FLUS) or suspicious for a follicular neoplasm (SFN) and their respective the European-Thyroid Imaging Reporting and Data System (EU-TIRADS) scores.

Methods: Forty-four pediatric patients at a single center with thyroid nodules classified as AUS/FLUS or SFN from August 2019 to December 2022 were retrospectively reviewed. Data on demographics, thyroid function, nodule size, and ultrasonographic features were collected.

View Article and Find Full Text PDF

Staphylococcus aureus is a significant cause of morbidity and mortality in pulmonary infections. Patients with autosomal-dominant hyper-IgE syndrome due to STAT3 deficiency are particularly susceptible to acquiring staphylococcal pneumonia associated with lung tissue destruction. Because macrophages are involved in both pathogen defense and inflammation, we investigated the impact of murine myeloid STAT3 deficiency on the macrophage phenotype in vitro and on pathogen clearance and inflammation during murine staphylococcal pneumonia.

View Article and Find Full Text PDF

The prognostic impact of PICALM::MLLT10 status in childhood leukaemia is not well described. Ten International Berlin Frankfurt Münster-affiliated study groups and the Children's Oncology Group collaborated in this multicentre retrospective study. The presence of the PICALM::MLLT10 fusion gene was confirmed by fluorescence in situ hybridization and/or RNA sequencing at participating sites.

View Article and Find Full Text PDF

The transcription factor Interferon Regulatory Factor 4 (IRF4) is central in control of T cell activation and differentiation. Deficiency of IRF4 results in severe immune deficiency and affects maturation and function of most if not all T cell subsets. Here we use mouse infection models for and to analyze the function of IRF4 in T helper (Th) 17 and Th2 cell responses, respectively.

View Article and Find Full Text PDF
Article Synopsis
  • Inborn errors of immunity (IEI) lead to immune dysfunction, causing increased risks of infections and diseases like cancer, as seen in a consanguineous family with Hodgkin lymphoma and severe immune issues.
  • Family members showed variable weaknesses in natural killer (NK) cells and cytotoxic T cell functions, and genetic analysis revealed harmful variants linked to specific disorders.
  • The study suggests that these genetic variants may worsen immune responses and overall disease severity, highlighting the importance of understanding genetic interactions for effective treatment strategies.
View Article and Find Full Text PDF

Objective: Repeated blood transfusions in women with beta-thalassemia major (BTM) may lead to iron overload and increase oxidative stress, consequently resulting in ovarian damage. The aim was to evaluate alterations in ovarian reserve in transfusion-dependent BTM patients over a time period of one year and to compare levels of anti-Mullerian hormone (AMH) in women with BTM and their healthy peers.

Material And Methods: This longitudinal prospective study was conducted in women with transfusion-dependent BTM at a tertiary level hospital.

View Article and Find Full Text PDF

Isocitrate Dehydrogenase 1 and 2 Mutations in Pediatric Neuroblastoma Patients.

Medeni Med J

June 2023

University of Health Sciences Turkey, Ankara Dr. Sami Ulus Maternity and Children's Health and Diseases Training and Research Hospital, Clinic of Pediatric Hematology and Oncology, Ankara, Turkey.

Objective: Neuroblastoma is one of the common tumors of childhood. The demonstration of new factors such as isocitrate dehydrogenase 1 (IDH1) and isocitrate dehydrogenase 2 (IDH2) mutations will be important in the diagnosis and treatment. IDH1 and IDH2 mutations have been found in many types of cancer, such as malignant gliomas, acute myeloid leukemias, chondrosarcoma, and thyroid carcinoma.

View Article and Find Full Text PDF

deletions are an established prognostic factor in childhood acute lymphoblastic leukemia (ALL). However, their relevance in patients with good risk genetics, namely :: and high hyperdiploid (HeH), ALL remains unclear. We assessed the prognostic impact of deletions in 939 :: and 968 HeH ALL patients by evaluating data from 16 trials from 9 study groups.

View Article and Find Full Text PDF

Blinatumomab Added to Chemotherapy in Infant Lymphoblastic Leukemia.

N Engl J Med

April 2023

From the Princess Máxima Center for Pediatric Oncology (I.M.S., P.E.S.-H., R.P.), and the Dutch Childhood Oncology Group (I.M.S., R.P.) - both in Utrecht, the Netherlands; Tettamanti Center (P.L.) and Biostatistics and Clinical Epidemiology (M.G.V.), Fondazione IRCCS San Gerardo dei Tintori, Monza, the School of Medicine and Surgery, University of Milano-Bicocca, Milan (M.G.V.), and the Department of Pediatric Hematology-Oncology and Cell and Gene Therapy, IRCCS Ospedale Pediatrico Bambino Gesù, Catholic University of the Sacred Heart, Rome (F.L.) - all in Italy; Australian and New Zealand Children's Hematology and Oncology Group, Perth Children's Hospital (R.S.K.), Telethon Kids Cancer Centre, Telethon Kids Institute, University of Western Australia (R.S.K.), and Curtin Medical School, Curtin University (R.S.K.) - all in Perth, WA, Australia; St. Anna Children's Hospital, Department of Pediatric Hematology and Oncology, Medical University of Vienna, and St. Anna Children's Cancer Research Institute - both in Vienna (A.A.); the German Cooperative Study Group for Childhood Acute Lymphoblastic Leukemia, Hamburg (G.E.) the Clinic of Pediatric Hematology and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg (G.E.), and the ALL-Berlin-Frankfurt-Münster (BFM) Group, University Medical Center Schleswig-Holstein, Campus Kiel, Kiel (M.S.) - all in Germany; the Department of Pediatrics and Adolescent Medicine, Rigshospitalet, University Hospital, Copenhagen (K.N.); Czech Working Group for Pediatric Hematology (J.S.) and CLIP (Childhood Leukemia Investigation Prague), Department of Pediatric Hematology and Oncology, Second Faculty of Medicine, Charles University and University Hospital Motol (J.S.) - all in Prague, Czech Republic; Hôpital Universitaire des Enfants Reine Fabiola, Brussels (A.F.); and the Department of Pediatric Hematology, University Robert Debre Hospital, Assistance Publique-Hôpitaux de Paris, Paris (B.B.).

Background: -rearranged acute lymphoblastic leukemia (ALL) in infants is an aggressive disease with 3-year event-free survival below 40%. Most relapses occur during treatment, with two thirds occurring within 1 year and 90% within 2 years after diagnosis. Outcomes have not improved in recent decades despite intensification of chemotherapy.

View Article and Find Full Text PDF

Epigenetic Modification of Mesenchymal Stromal Cells Derived from Bone Marrow and Embryonal Tumors to Facilitate Immunotherapeutic Approaches in Pediatric Malignancies.

Curr Issues Mol Biol

March 2023

Division of Pediatric Stem Cell Transplantation and Immunology, Clinic of Pediatric Hematology and Oncology, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246 Hamburg, Germany.

Mesenchymal stromal cells (MSC) are part of the bone marrow architecture and contribute to the homeostasis of hematopoietic stem cells. Moreover, they are known to regulate immune effector cells. These properties of MSC are pivotal under physiologic conditions, and they may aberrantly also protect malignant cells.

View Article and Find Full Text PDF

Introduction: In 2020, the new nationwide protocol of prophylaxis in Polish plasma-derived FVIII (pdFVIII) previously treated patients (PTPs) with severe hemophilia A (sHA) was introduced, resulting in the necessity of switching from pdFVIII to recombinant FVIII (octocog-alpha; rFVIII). The study aimed to: (1) assess the safety of switching from pdFVIII to rFVIII, (2) assess the safety and efficacy of pharmacokinetically based (PK-based) personalized prophylaxis in severe hemophilia A.

Patients And Methods: 151 children and adolescents receiving prophylaxis with a standard dose (40 U/kg 3 x weekly) of pdFVIII were included in this study.

View Article and Find Full Text PDF

Background And Purpose: Intrachromosomal amplification of chromosome 21 (iAMP21) is a rare subtype of B-cell precursor acute lymphoblastic leukaemia (BCP-ALL). It is unknown how iAMP21 contributes to leukaemia. The currently known commonly amplified region is 5.

View Article and Find Full Text PDF